A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma

International Journal of Proteomics

NúriaMalats¹  PetterSkoog¹  Francisco X.Real¹  HelenaPersson¹  ChristerWingren¹  MiquelPorta¹  Carl A. K.Borrebaeck¹  Anna S.Gerdtsson¹  AnnaSäll¹ 

DOI  :  10.1155/2015/587250

学科分类：生物化学/生物物理

来源: Hindawi Publishing Corporation

【 摘 要 】

Background.Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with rapid tumor progression and poor prognosis. This study was motivated by the lack of sensitive and specific PDAC biomarkers and aimed to identify a diagnostic, serum protein signature for PDAC.Methods.To mimic a real life test situation, a multicenter trial comprising a serum sample cohort, including 338 patients with either PDAC or other pancreatic diseases (OPD) and controls with nonpancreatic conditions (NPC), was analyzed on 293-plex recombinant antibody microarrays targeting immunoregulatory and cancer-associated antigens.Results.Serum samples collected from different hospitals were analyzed and showed that (i) sampling from five different hospitals could not be identified as a preanalytical variable and (ii) a multiplexed biomarker signature could be identified, utilizing up to 10 serum markers that could discriminate PDAC from controls, with sensitivities and specificities in the 91–100% range. The first protein profiles associated with the location of the primary tumor in the pancreas could also be identified.Conclusions.The results demonstrate that robust enough serum signatures could be identified in a multicenter trial, potentially contributing to the development of a multiplexed biomarker immunoassay for improved PDAC diagnosis.

【 授权许可】

Unknown